Global Drugs for Vulvovaginal Candidiasis Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 1330 million in 2025 and is forecast to a readjusted size of US$ 1910 million by 2032 with a CAGR of 5.4% during review period.
Drugs for vulvovaginal candidiasis are used to prevent and treat infections of the female vulva and vagina caused by Candida albicans and other Candida species. These drugs include topical formulations such as vaginal suppositories and gels, as well as systemic oral antifungals. They work by inhibiting fungal cell membrane synthesis or disrupting metabolic processes, providing rapid relief from symptoms such as itching, burning, and abnormal discharge, while reducing recurrence. Current development trends emphasize high selectivity, low toxicity, and combination therapies that regulate vaginal microecology to meet individualized patient needs. With increasing awareness of women’s health and improved access to healthcare, drugs for vulvovaginal candidiasis are becoming a significant segment of the global gynecological pharmaceutical market. In 2024, global Drugs for vulvovaginal candidiasis production reached approximately 354 m units, with an average global market price of around US$ 3.5 perunit.The average gross profit margin of this product is around 50%.
The market for drugs treating vulvovaginal candidiasis is driven by increased awareness of women’s health, expanded outpatient and community healthcare coverage, and supportive reproductive health policies. Annual reports of leading pharmaceutical companies indicate continued launches of new topical and systemic antifungal drugs, with improved formulations and administration routes enhancing patient adherence. Epidemiological data show recurrent infections and resistance issues prompting healthcare providers and patients to seek higher efficacy and safety, creating opportunities for innovative drugs and combination therapies. Growth in online pharmaceutical sales and telemedicine further diversifies product promotion and patient education channels, facilitating market penetration.Despite strong demand, the industry faces challenges such as stringent regulatory approvals, patent barriers, and price competition. New drug development requires lengthy cycles and high clinical validation costs, while differences in adverse reactions and patient adherence between topical and systemic therapies may affect market acceptance. In some emerging markets, uneven distribution of healthcare resources limits product accessibility. Additionally, increasing antifungal resistance may necessitate frequent adjustments in treatment protocols, adding R&D pressure and complexity to inventory management for pharmaceutical companies.Clinical demand is becoming more precise, personalized, and convenient. Patients and healthcare providers prefer short-course, fast-acting, low-side-effect therapies that can be combined with microecological regulation. Gynecological outpatient clinics, community healthcare centers, and online medical platforms have become key channels for sales and usage, promoting the development of convenient formulations such as vaginal gels and sustained-release suppositories, as well as digital management services. Going forward, personalized treatment, recurrence prevention, and microecological combination therapies will shape downstream demand, driving innovation in product portfolios and service models.Core raw materials for drugs treating vulvovaginal candidiasis include active antifungal ingredients (e.g., fluconazole, itraconazole, clotrimazole), pharmaceutical excipients (matrix materials, lubricants, sustained-release carriers), and packaging materials. Annual reports indicate that supply of high-purity active ingredients is concentrated, relying on stable international or domestic suppliers. Raw material price fluctuations, cross-border supply chains, and regulatory changes may affect production costs and delivery timelines. By establishing long-term partnerships, multi-source procurement, and optimized manufacturing processes, companies can ensure stable supply while controlling costs and supporting the development of new formulations and innovative combination therapy strategies.
This report is a detailed and comprehensive analysis for global Drugs for Vulvovaginal Candidiasis market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Drugs for Vulvovaginal Candidiasis market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Drugs for Vulvovaginal Candidiasis market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Drugs for Vulvovaginal Candidiasis market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Drugs for Vulvovaginal Candidiasis market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for Vulvovaginal Candidiasis
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for Vulvovaginal Candidiasis market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Perrigo, J & J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical, Kingyork Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Drugs for Vulvovaginal Candidiasis market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Drugs for Vulvovaginal Candidiasis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Drugs for Vulvovaginal Candidiasis, with price, sales quantity, revenue, and global market share of Drugs for Vulvovaginal Candidiasis from 2021 to 2026.
Chapter 3, the Drugs for Vulvovaginal Candidiasis competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Vulvovaginal Candidiasis breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Drugs for Vulvovaginal Candidiasis market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for Vulvovaginal Candidiasis.
Chapter 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, customers, research findings and conclusion.
Drugs for vulvovaginal candidiasis are used to prevent and treat infections of the female vulva and vagina caused by Candida albicans and other Candida species. These drugs include topical formulations such as vaginal suppositories and gels, as well as systemic oral antifungals. They work by inhibiting fungal cell membrane synthesis or disrupting metabolic processes, providing rapid relief from symptoms such as itching, burning, and abnormal discharge, while reducing recurrence. Current development trends emphasize high selectivity, low toxicity, and combination therapies that regulate vaginal microecology to meet individualized patient needs. With increasing awareness of women’s health and improved access to healthcare, drugs for vulvovaginal candidiasis are becoming a significant segment of the global gynecological pharmaceutical market. In 2024, global Drugs for vulvovaginal candidiasis production reached approximately 354 m units, with an average global market price of around US$ 3.5 perunit.The average gross profit margin of this product is around 50%.
The market for drugs treating vulvovaginal candidiasis is driven by increased awareness of women’s health, expanded outpatient and community healthcare coverage, and supportive reproductive health policies. Annual reports of leading pharmaceutical companies indicate continued launches of new topical and systemic antifungal drugs, with improved formulations and administration routes enhancing patient adherence. Epidemiological data show recurrent infections and resistance issues prompting healthcare providers and patients to seek higher efficacy and safety, creating opportunities for innovative drugs and combination therapies. Growth in online pharmaceutical sales and telemedicine further diversifies product promotion and patient education channels, facilitating market penetration.Despite strong demand, the industry faces challenges such as stringent regulatory approvals, patent barriers, and price competition. New drug development requires lengthy cycles and high clinical validation costs, while differences in adverse reactions and patient adherence between topical and systemic therapies may affect market acceptance. In some emerging markets, uneven distribution of healthcare resources limits product accessibility. Additionally, increasing antifungal resistance may necessitate frequent adjustments in treatment protocols, adding R&D pressure and complexity to inventory management for pharmaceutical companies.Clinical demand is becoming more precise, personalized, and convenient. Patients and healthcare providers prefer short-course, fast-acting, low-side-effect therapies that can be combined with microecological regulation. Gynecological outpatient clinics, community healthcare centers, and online medical platforms have become key channels for sales and usage, promoting the development of convenient formulations such as vaginal gels and sustained-release suppositories, as well as digital management services. Going forward, personalized treatment, recurrence prevention, and microecological combination therapies will shape downstream demand, driving innovation in product portfolios and service models.Core raw materials for drugs treating vulvovaginal candidiasis include active antifungal ingredients (e.g., fluconazole, itraconazole, clotrimazole), pharmaceutical excipients (matrix materials, lubricants, sustained-release carriers), and packaging materials. Annual reports indicate that supply of high-purity active ingredients is concentrated, relying on stable international or domestic suppliers. Raw material price fluctuations, cross-border supply chains, and regulatory changes may affect production costs and delivery timelines. By establishing long-term partnerships, multi-source procurement, and optimized manufacturing processes, companies can ensure stable supply while controlling costs and supporting the development of new formulations and innovative combination therapy strategies.
This report is a detailed and comprehensive analysis for global Drugs for Vulvovaginal Candidiasis market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Drugs for Vulvovaginal Candidiasis market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Drugs for Vulvovaginal Candidiasis market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Drugs for Vulvovaginal Candidiasis market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2021-2032
Global Drugs for Vulvovaginal Candidiasis market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for Vulvovaginal Candidiasis
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for Vulvovaginal Candidiasis market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Perrigo, J & J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical, Kingyork Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Drugs for Vulvovaginal Candidiasis market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Cream
- Pessary
- Other
- Hospital & Clinic
- Pharmacy
- Bayer
- Perrigo
- J & J
- Pfizer
- Bristol-Myers Squibb
- Effik
- Teva
- Sanofi
- Cisen Pharmaceutical
- Kingyork Group
- Teva Pharmaceuticals
- Lupin Pharmaceuticals
- Globela Pharma
- Yuanda Medical
- Huarun Medical
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Drugs for Vulvovaginal Candidiasis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Drugs for Vulvovaginal Candidiasis, with price, sales quantity, revenue, and global market share of Drugs for Vulvovaginal Candidiasis from 2021 to 2026.
Chapter 3, the Drugs for Vulvovaginal Candidiasis competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Vulvovaginal Candidiasis breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Drugs for Vulvovaginal Candidiasis market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for Vulvovaginal Candidiasis.
Chapter 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Cream
1.3.3 Pessary
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Hospital & Clinic
1.4.3 Pharmacy
1.5 Global Drugs for Vulvovaginal Candidiasis Market Size & Forecast
1.5.1 Global Drugs for Vulvovaginal Candidiasis Consumption Value (2021 & 2025 & 2032)
1.5.2 Global Drugs for Vulvovaginal Candidiasis Sales Quantity (2021-2032)
1.5.3 Global Drugs for Vulvovaginal Candidiasis Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Product and Services
2.1.4 Bayer Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Bayer Recent Developments/Updates
2.2 Perrigo
2.2.1 Perrigo Details
2.2.2 Perrigo Major Business
2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Product and Services
2.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Perrigo Recent Developments/Updates
2.3 J & J
2.3.1 J & J Details
2.3.2 J & J Major Business
2.3.3 J & J Drugs for Vulvovaginal Candidiasis Product and Services
2.3.4 J & J Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 J & J Recent Developments/Updates
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Product and Services
2.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Pfizer Recent Developments/Updates
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product and Services
2.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Bristol-Myers Squibb Recent Developments/Updates
2.6 Effik
2.6.1 Effik Details
2.6.2 Effik Major Business
2.6.3 Effik Drugs for Vulvovaginal Candidiasis Product and Services
2.6.4 Effik Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Effik Recent Developments/Updates
2.7 Teva
2.7.1 Teva Details
2.7.2 Teva Major Business
2.7.3 Teva Drugs for Vulvovaginal Candidiasis Product and Services
2.7.4 Teva Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Teva Recent Developments/Updates
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Product and Services
2.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Sanofi Recent Developments/Updates
2.9 Cisen Pharmaceutical
2.9.1 Cisen Pharmaceutical Details
2.9.2 Cisen Pharmaceutical Major Business
2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product and Services
2.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Cisen Pharmaceutical Recent Developments/Updates
2.10 Kingyork Group
2.10.1 Kingyork Group Details
2.10.2 Kingyork Group Major Business
2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Product and Services
2.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Kingyork Group Recent Developments/Updates
2.11 Teva Pharmaceuticals
2.11.1 Teva Pharmaceuticals Details
2.11.2 Teva Pharmaceuticals Major Business
2.11.3 Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product and Services
2.11.4 Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Teva Pharmaceuticals Recent Developments/Updates
2.12 Lupin Pharmaceuticals
2.12.1 Lupin Pharmaceuticals Details
2.12.2 Lupin Pharmaceuticals Major Business
2.12.3 Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product and Services
2.12.4 Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Lupin Pharmaceuticals Recent Developments/Updates
2.13 Globela Pharma
2.13.1 Globela Pharma Details
2.13.2 Globela Pharma Major Business
2.13.3 Globela Pharma Drugs for Vulvovaginal Candidiasis Product and Services
2.13.4 Globela Pharma Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Globela Pharma Recent Developments/Updates
2.14 Yuanda Medical
2.14.1 Yuanda Medical Details
2.14.2 Yuanda Medical Major Business
2.14.3 Yuanda Medical Drugs for Vulvovaginal Candidiasis Product and Services
2.14.4 Yuanda Medical Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Yuanda Medical Recent Developments/Updates
2.15 Huarun Medical
2.15.1 Huarun Medical Details
2.15.2 Huarun Medical Major Business
2.15.3 Huarun Medical Drugs for Vulvovaginal Candidiasis Product and Services
2.15.4 Huarun Medical Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Huarun Medical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: DRUGS FOR VULVOVAGINAL CANDIDIASIS BY MANUFACTURER
3.1 Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Manufacturer (2021-2026)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2021-2026)
3.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Drugs for Vulvovaginal Candidiasis by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2025
3.4.3 Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2025
3.5 Drugs for Vulvovaginal Candidiasis Market: Overall Company Footprint Analysis
3.5.1 Drugs for Vulvovaginal Candidiasis Market: Region Footprint
3.5.2 Drugs for Vulvovaginal Candidiasis Market: Company Product Type Footprint
3.5.3 Drugs for Vulvovaginal Candidiasis Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2021-2032)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2032)
4.1.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2021-2032)
4.2 North America Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
4.3 Europe Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
4.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
4.5 South America Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
4.6 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
5.2 Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type (2021-2032)
5.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
6.2 Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application (2021-2032)
6.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
7.2 North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
7.3 North America Drugs for Vulvovaginal Candidiasis Market Size by Country
7.3.1 North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2032)
7.3.2 North America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
8.2 Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
8.3 Europe Drugs for Vulvovaginal Candidiasis Market Size by Country
8.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2032)
8.3.2 Europe Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Size by Region
9.3.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
10.2 South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
10.3 South America Drugs for Vulvovaginal Candidiasis Market Size by Country
10.3.1 South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2032)
10.3.2 South America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Drugs for Vulvovaginal Candidiasis Market Size by Country
11.3.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Drugs for Vulvovaginal Candidiasis Market Drivers
12.2 Drugs for Vulvovaginal Candidiasis Market Restraints
12.3 Drugs for Vulvovaginal Candidiasis Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Drugs for Vulvovaginal Candidiasis and Key Manufacturers
13.2 Manufacturing Costs Percentage of Drugs for Vulvovaginal Candidiasis
13.3 Drugs for Vulvovaginal Candidiasis Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Drugs for Vulvovaginal Candidiasis Typical Distributors
14.3 Drugs for Vulvovaginal Candidiasis Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Cream
1.3.3 Pessary
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Hospital & Clinic
1.4.3 Pharmacy
1.5 Global Drugs for Vulvovaginal Candidiasis Market Size & Forecast
1.5.1 Global Drugs for Vulvovaginal Candidiasis Consumption Value (2021 & 2025 & 2032)
1.5.2 Global Drugs for Vulvovaginal Candidiasis Sales Quantity (2021-2032)
1.5.3 Global Drugs for Vulvovaginal Candidiasis Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Product and Services
2.1.4 Bayer Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Bayer Recent Developments/Updates
2.2 Perrigo
2.2.1 Perrigo Details
2.2.2 Perrigo Major Business
2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Product and Services
2.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Perrigo Recent Developments/Updates
2.3 J & J
2.3.1 J & J Details
2.3.2 J & J Major Business
2.3.3 J & J Drugs for Vulvovaginal Candidiasis Product and Services
2.3.4 J & J Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 J & J Recent Developments/Updates
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Product and Services
2.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Pfizer Recent Developments/Updates
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product and Services
2.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Bristol-Myers Squibb Recent Developments/Updates
2.6 Effik
2.6.1 Effik Details
2.6.2 Effik Major Business
2.6.3 Effik Drugs for Vulvovaginal Candidiasis Product and Services
2.6.4 Effik Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Effik Recent Developments/Updates
2.7 Teva
2.7.1 Teva Details
2.7.2 Teva Major Business
2.7.3 Teva Drugs for Vulvovaginal Candidiasis Product and Services
2.7.4 Teva Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Teva Recent Developments/Updates
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Product and Services
2.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Sanofi Recent Developments/Updates
2.9 Cisen Pharmaceutical
2.9.1 Cisen Pharmaceutical Details
2.9.2 Cisen Pharmaceutical Major Business
2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product and Services
2.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Cisen Pharmaceutical Recent Developments/Updates
2.10 Kingyork Group
2.10.1 Kingyork Group Details
2.10.2 Kingyork Group Major Business
2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Product and Services
2.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Kingyork Group Recent Developments/Updates
2.11 Teva Pharmaceuticals
2.11.1 Teva Pharmaceuticals Details
2.11.2 Teva Pharmaceuticals Major Business
2.11.3 Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product and Services
2.11.4 Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Teva Pharmaceuticals Recent Developments/Updates
2.12 Lupin Pharmaceuticals
2.12.1 Lupin Pharmaceuticals Details
2.12.2 Lupin Pharmaceuticals Major Business
2.12.3 Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product and Services
2.12.4 Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Lupin Pharmaceuticals Recent Developments/Updates
2.13 Globela Pharma
2.13.1 Globela Pharma Details
2.13.2 Globela Pharma Major Business
2.13.3 Globela Pharma Drugs for Vulvovaginal Candidiasis Product and Services
2.13.4 Globela Pharma Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Globela Pharma Recent Developments/Updates
2.14 Yuanda Medical
2.14.1 Yuanda Medical Details
2.14.2 Yuanda Medical Major Business
2.14.3 Yuanda Medical Drugs for Vulvovaginal Candidiasis Product and Services
2.14.4 Yuanda Medical Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Yuanda Medical Recent Developments/Updates
2.15 Huarun Medical
2.15.1 Huarun Medical Details
2.15.2 Huarun Medical Major Business
2.15.3 Huarun Medical Drugs for Vulvovaginal Candidiasis Product and Services
2.15.4 Huarun Medical Drugs for Vulvovaginal Candidiasis Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Huarun Medical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: DRUGS FOR VULVOVAGINAL CANDIDIASIS BY MANUFACTURER
3.1 Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Manufacturer (2021-2026)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2021-2026)
3.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Drugs for Vulvovaginal Candidiasis by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2025
3.4.3 Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2025
3.5 Drugs for Vulvovaginal Candidiasis Market: Overall Company Footprint Analysis
3.5.1 Drugs for Vulvovaginal Candidiasis Market: Region Footprint
3.5.2 Drugs for Vulvovaginal Candidiasis Market: Company Product Type Footprint
3.5.3 Drugs for Vulvovaginal Candidiasis Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2021-2032)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2032)
4.1.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2021-2032)
4.2 North America Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
4.3 Europe Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
4.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
4.5 South America Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
4.6 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
5.2 Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type (2021-2032)
5.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
6.2 Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application (2021-2032)
6.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
7.2 North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
7.3 North America Drugs for Vulvovaginal Candidiasis Market Size by Country
7.3.1 North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2032)
7.3.2 North America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
8.2 Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
8.3 Europe Drugs for Vulvovaginal Candidiasis Market Size by Country
8.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2032)
8.3.2 Europe Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Size by Region
9.3.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
10.2 South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
10.3 South America Drugs for Vulvovaginal Candidiasis Market Size by Country
10.3.1 South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2032)
10.3.2 South America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Drugs for Vulvovaginal Candidiasis Market Size by Country
11.3.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Drugs for Vulvovaginal Candidiasis Market Drivers
12.2 Drugs for Vulvovaginal Candidiasis Market Restraints
12.3 Drugs for Vulvovaginal Candidiasis Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Drugs for Vulvovaginal Candidiasis and Key Manufacturers
13.2 Manufacturing Costs Percentage of Drugs for Vulvovaginal Candidiasis
13.3 Drugs for Vulvovaginal Candidiasis Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Drugs for Vulvovaginal Candidiasis Typical Distributors
14.3 Drugs for Vulvovaginal Candidiasis Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Bayer Basic Information, Manufacturing Base and Competitors
Table 4. Bayer Major Business
Table 5. Bayer Drugs for Vulvovaginal Candidiasis Product and Services
Table 6. Bayer Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Bayer Recent Developments/Updates
Table 8. Perrigo Basic Information, Manufacturing Base and Competitors
Table 9. Perrigo Major Business
Table 10. Perrigo Drugs for Vulvovaginal Candidiasis Product and Services
Table 11. Perrigo Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Perrigo Recent Developments/Updates
Table 13. J & J Basic Information, Manufacturing Base and Competitors
Table 14. J & J Major Business
Table 15. J & J Drugs for Vulvovaginal Candidiasis Product and Services
Table 16. J & J Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. J & J Recent Developments/Updates
Table 18. Pfizer Basic Information, Manufacturing Base and Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Drugs for Vulvovaginal Candidiasis Product and Services
Table 21. Pfizer Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. Pfizer Recent Developments/Updates
Table 23. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 24. Bristol-Myers Squibb Major Business
Table 25. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product and Services
Table 26. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. Bristol-Myers Squibb Recent Developments/Updates
Table 28. Effik Basic Information, Manufacturing Base and Competitors
Table 29. Effik Major Business
Table 30. Effik Drugs for Vulvovaginal Candidiasis Product and Services
Table 31. Effik Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. Effik Recent Developments/Updates
Table 33. Teva Basic Information, Manufacturing Base and Competitors
Table 34. Teva Major Business
Table 35. Teva Drugs for Vulvovaginal Candidiasis Product and Services
Table 36. Teva Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 37. Teva Recent Developments/Updates
Table 38. Sanofi Basic Information, Manufacturing Base and Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Drugs for Vulvovaginal Candidiasis Product and Services
Table 41. Sanofi Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 42. Sanofi Recent Developments/Updates
Table 43. Cisen Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 44. Cisen Pharmaceutical Major Business
Table 45. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product and Services
Table 46. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 47. Cisen Pharmaceutical Recent Developments/Updates
Table 48. Kingyork Group Basic Information, Manufacturing Base and Competitors
Table 49. Kingyork Group Major Business
Table 50. Kingyork Group Drugs for Vulvovaginal Candidiasis Product and Services
Table 51. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 52. Kingyork Group Recent Developments/Updates
Table 53. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 54. Teva Pharmaceuticals Major Business
Table 55. Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product and Services
Table 56. Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 57. Teva Pharmaceuticals Recent Developments/Updates
Table 58. Lupin Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 59. Lupin Pharmaceuticals Major Business
Table 60. Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product and Services
Table 61. Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 62. Lupin Pharmaceuticals Recent Developments/Updates
Table 63. Globela Pharma Basic Information, Manufacturing Base and Competitors
Table 64. Globela Pharma Major Business
Table 65. Globela Pharma Drugs for Vulvovaginal Candidiasis Product and Services
Table 66. Globela Pharma Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 67. Globela Pharma Recent Developments/Updates
Table 68. Yuanda Medical Basic Information, Manufacturing Base and Competitors
Table 69. Yuanda Medical Major Business
Table 70. Yuanda Medical Drugs for Vulvovaginal Candidiasis Product and Services
Table 71. Yuanda Medical Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 72. Yuanda Medical Recent Developments/Updates
Table 73. Huarun Medical Basic Information, Manufacturing Base and Competitors
Table 74. Huarun Medical Major Business
Table 75. Huarun Medical Drugs for Vulvovaginal Candidiasis Product and Services
Table 76. Huarun Medical Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 77. Huarun Medical Recent Developments/Updates
Table 78. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 79. Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2021-2026) & (USD Million)
Table 80. Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturer (2021-2026) & (USD/Unit)
Table 81. Market Position of Manufacturers in Drugs for Vulvovaginal Candidiasis, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 82. Head Office and Drugs for Vulvovaginal Candidiasis Production Site of Key Manufacturer
Table 83. Drugs for Vulvovaginal Candidiasis Market: Company Product Type Footprint
Table 84. Drugs for Vulvovaginal Candidiasis Market: Company Product Application Footprint
Table 85. Drugs for Vulvovaginal Candidiasis New Market Entrants and Barriers to Market Entry
Table 86. Drugs for Vulvovaginal Candidiasis Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 88. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2021-2026) & (K Units)
Table 89. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2027-2032) & (K Units)
Table 90. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2026) & (USD Million)
Table 91. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2027-2032) & (USD Million)
Table 92. Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2021-2026) & (USD/Unit)
Table 93. Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2027-2032) & (USD/Unit)
Table 94. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 95. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 96. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type (2021-2026) & (USD Million)
Table 97. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type (2027-2032) & (USD Million)
Table 98. Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2021-2026) & (USD/Unit)
Table 99. Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2027-2032) & (USD/Unit)
Table 100. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 101. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 102. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application (2021-2026) & (USD Million)
Table 103. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application (2027-2032) & (USD Million)
Table 104. Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2021-2026) & (USD/Unit)
Table 105. Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2027-2032) & (USD/Unit)
Table 106. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 107. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 108. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 109. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 110. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2026) & (K Units)
Table 111. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2027-2032) & (K Units)
Table 112. North America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2026) & (USD Million)
Table 113. North America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2027-2032) & (USD Million)
Table 114. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 115. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 116. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 117. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 118. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2026) & (K Units)
Table 119. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2027-2032) & (K Units)
Table 120. Europe Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2026) & (USD Million)
Table 121. Europe Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2027-2032) & (USD Million)
Table 122. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 123. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 124. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 125. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 126. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2021-2026) & (K Units)
Table 127. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2027-2032) & (K Units)
Table 128. Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2026) & (USD Million)
Table 129. Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2027-2032) & (USD Million)
Table 130. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 131. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 132. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 133. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 134. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2026) & (K Units)
Table 135. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2027-2032) & (K Units)
Table 136. South America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2026) & (USD Million)
Table 137. South America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2027-2032) & (USD Million)
Table 138. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 139. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 140. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 141. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 142. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2026) & (K Units)
Table 143. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2027-2032) & (K Units)
Table 144. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2026) & (USD Million)
Table 145. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2027-2032) & (USD Million)
Table 146. Drugs for Vulvovaginal Candidiasis Raw Material
Table 147. Key Manufacturers of Drugs for Vulvovaginal Candidiasis Raw Materials
Table 148. Drugs for Vulvovaginal Candidiasis Typical Distributors
Table 149. Drugs for Vulvovaginal Candidiasis Typical Customers
Table 1. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Bayer Basic Information, Manufacturing Base and Competitors
Table 4. Bayer Major Business
Table 5. Bayer Drugs for Vulvovaginal Candidiasis Product and Services
Table 6. Bayer Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Bayer Recent Developments/Updates
Table 8. Perrigo Basic Information, Manufacturing Base and Competitors
Table 9. Perrigo Major Business
Table 10. Perrigo Drugs for Vulvovaginal Candidiasis Product and Services
Table 11. Perrigo Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Perrigo Recent Developments/Updates
Table 13. J & J Basic Information, Manufacturing Base and Competitors
Table 14. J & J Major Business
Table 15. J & J Drugs for Vulvovaginal Candidiasis Product and Services
Table 16. J & J Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. J & J Recent Developments/Updates
Table 18. Pfizer Basic Information, Manufacturing Base and Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Drugs for Vulvovaginal Candidiasis Product and Services
Table 21. Pfizer Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. Pfizer Recent Developments/Updates
Table 23. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 24. Bristol-Myers Squibb Major Business
Table 25. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product and Services
Table 26. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. Bristol-Myers Squibb Recent Developments/Updates
Table 28. Effik Basic Information, Manufacturing Base and Competitors
Table 29. Effik Major Business
Table 30. Effik Drugs for Vulvovaginal Candidiasis Product and Services
Table 31. Effik Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. Effik Recent Developments/Updates
Table 33. Teva Basic Information, Manufacturing Base and Competitors
Table 34. Teva Major Business
Table 35. Teva Drugs for Vulvovaginal Candidiasis Product and Services
Table 36. Teva Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 37. Teva Recent Developments/Updates
Table 38. Sanofi Basic Information, Manufacturing Base and Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Drugs for Vulvovaginal Candidiasis Product and Services
Table 41. Sanofi Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 42. Sanofi Recent Developments/Updates
Table 43. Cisen Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 44. Cisen Pharmaceutical Major Business
Table 45. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product and Services
Table 46. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 47. Cisen Pharmaceutical Recent Developments/Updates
Table 48. Kingyork Group Basic Information, Manufacturing Base and Competitors
Table 49. Kingyork Group Major Business
Table 50. Kingyork Group Drugs for Vulvovaginal Candidiasis Product and Services
Table 51. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 52. Kingyork Group Recent Developments/Updates
Table 53. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 54. Teva Pharmaceuticals Major Business
Table 55. Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product and Services
Table 56. Teva Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 57. Teva Pharmaceuticals Recent Developments/Updates
Table 58. Lupin Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 59. Lupin Pharmaceuticals Major Business
Table 60. Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Product and Services
Table 61. Lupin Pharmaceuticals Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 62. Lupin Pharmaceuticals Recent Developments/Updates
Table 63. Globela Pharma Basic Information, Manufacturing Base and Competitors
Table 64. Globela Pharma Major Business
Table 65. Globela Pharma Drugs for Vulvovaginal Candidiasis Product and Services
Table 66. Globela Pharma Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 67. Globela Pharma Recent Developments/Updates
Table 68. Yuanda Medical Basic Information, Manufacturing Base and Competitors
Table 69. Yuanda Medical Major Business
Table 70. Yuanda Medical Drugs for Vulvovaginal Candidiasis Product and Services
Table 71. Yuanda Medical Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 72. Yuanda Medical Recent Developments/Updates
Table 73. Huarun Medical Basic Information, Manufacturing Base and Competitors
Table 74. Huarun Medical Major Business
Table 75. Huarun Medical Drugs for Vulvovaginal Candidiasis Product and Services
Table 76. Huarun Medical Drugs for Vulvovaginal Candidiasis Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 77. Huarun Medical Recent Developments/Updates
Table 78. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 79. Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2021-2026) & (USD Million)
Table 80. Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturer (2021-2026) & (USD/Unit)
Table 81. Market Position of Manufacturers in Drugs for Vulvovaginal Candidiasis, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 82. Head Office and Drugs for Vulvovaginal Candidiasis Production Site of Key Manufacturer
Table 83. Drugs for Vulvovaginal Candidiasis Market: Company Product Type Footprint
Table 84. Drugs for Vulvovaginal Candidiasis Market: Company Product Application Footprint
Table 85. Drugs for Vulvovaginal Candidiasis New Market Entrants and Barriers to Market Entry
Table 86. Drugs for Vulvovaginal Candidiasis Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 88. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2021-2026) & (K Units)
Table 89. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2027-2032) & (K Units)
Table 90. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2026) & (USD Million)
Table 91. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2027-2032) & (USD Million)
Table 92. Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2021-2026) & (USD/Unit)
Table 93. Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2027-2032) & (USD/Unit)
Table 94. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 95. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 96. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type (2021-2026) & (USD Million)
Table 97. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Type (2027-2032) & (USD Million)
Table 98. Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2021-2026) & (USD/Unit)
Table 99. Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2027-2032) & (USD/Unit)
Table 100. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 101. Global Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 102. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application (2021-2026) & (USD Million)
Table 103. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application (2027-2032) & (USD Million)
Table 104. Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2021-2026) & (USD/Unit)
Table 105. Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2027-2032) & (USD/Unit)
Table 106. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 107. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 108. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 109. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 110. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2026) & (K Units)
Table 111. North America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2027-2032) & (K Units)
Table 112. North America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2026) & (USD Million)
Table 113. North America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2027-2032) & (USD Million)
Table 114. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 115. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 116. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 117. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 118. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2026) & (K Units)
Table 119. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2027-2032) & (K Units)
Table 120. Europe Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2026) & (USD Million)
Table 121. Europe Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2027-2032) & (USD Million)
Table 122. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 123. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 124. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 125. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 126. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2021-2026) & (K Units)
Table 127. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity by Region (2027-2032) & (K Units)
Table 128. Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2021-2026) & (USD Million)
Table 129. Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value by Region (2027-2032) & (USD Million)
Table 130. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 131. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 132. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 133. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 134. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2026) & (K Units)
Table 135. South America Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2027-2032) & (K Units)
Table 136. South America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2026) & (USD Million)
Table 137. South America Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2027-2032) & (USD Million)
Table 138. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2021-2026) & (K Units)
Table 139. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Type (2027-2032) & (K Units)
Table 140. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2021-2026) & (K Units)
Table 141. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Application (2027-2032) & (K Units)
Table 142. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2021-2026) & (K Units)
Table 143. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity by Country (2027-2032) & (K Units)
Table 144. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2021-2026) & (USD Million)
Table 145. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value by Country (2027-2032) & (USD Million)
Table 146. Drugs for Vulvovaginal Candidiasis Raw Material
Table 147. Key Manufacturers of Drugs for Vulvovaginal Candidiasis Raw Materials
Table 148. Drugs for Vulvovaginal Candidiasis Typical Distributors
Table 149. Drugs for Vulvovaginal Candidiasis Typical Customers
LIST OF FIGURES
Figure 1. Drugs for Vulvovaginal Candidiasis Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type in 2025
Figure 4. Cream Examples
Figure 5. Pessary Examples
Figure 6. Other Examples
Figure 7. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application in 2025
Figure 9. Hospital & Clinic Examples
Figure 10. Pharmacy Examples
Figure 11. Global Drugs for Vulvovaginal Candidiasis Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 12. Global Drugs for Vulvovaginal Candidiasis Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 13. Global Drugs for Vulvovaginal Candidiasis Sales Quantity (2021-2032) & (K Units)
Figure 14. Global Drugs for Vulvovaginal Candidiasis Price (2021-2032) & (USD/Unit)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Manufacturer in 2025
Figure 16. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2025
Figure 17. Producer Shipments of Drugs for Vulvovaginal Candidiasis by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 18. Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2025
Figure 19. Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2025
Figure 20. Global Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Region (2021-2032)
Figure 21. Global Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Region (2021-2032)
Figure 22. North America Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 23. Europe Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 24. Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 25. South America Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 26. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 27. Global Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 28. Global Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Type (2021-2032)
Figure 29. Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2021-2032) & (USD/Unit)
Figure 30. Global Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 31. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2021-2032)
Figure 32. Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2021-2032) & (USD/Unit)
Figure 33. North America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 34. North America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 35. North America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Country (2021-2032)
Figure 36. North America Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Country (2021-2032)
Figure 37. United States Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 38. Canada Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 39. Mexico Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 40. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 41. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 42. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Country (2021-2032)
Figure 43. Europe Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Country (2021-2032)
Figure 44. Germany Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 45. France Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 46. United Kingdom Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 47. Russia Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 48. Italy Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 49. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 50. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 51. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Region (2021-2032)
Figure 52. Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Region (2021-2032)
Figure 53. China Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 54. Japan Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 55. South Korea Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 56. India Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 57. Southeast Asia Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 58. Australia Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 59. South America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 60. South America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 61. South America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Country (2021-2032)
Figure 62. South America Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Country (2021-2032)
Figure 63. Brazil Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 64. Argentina Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 65. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 66. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 67. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Country (2021-2032)
Figure 68. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Country (2021-2032)
Figure 69. Turkey Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 70. Egypt Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 71. Saudi Arabia Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 72. South Africa Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 73. Drugs for Vulvovaginal Candidiasis Market Drivers
Figure 74. Drugs for Vulvovaginal Candidiasis Market Restraints
Figure 75. Drugs for Vulvovaginal Candidiasis Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Drugs for Vulvovaginal Candidiasis in 2025
Figure 78. Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
Figure 79. Drugs for Vulvovaginal Candidiasis Industrial Chain
Figure 80. Sales Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Figure 1. Drugs for Vulvovaginal Candidiasis Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type in 2025
Figure 4. Cream Examples
Figure 5. Pessary Examples
Figure 6. Other Examples
Figure 7. Global Drugs for Vulvovaginal Candidiasis Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application in 2025
Figure 9. Hospital & Clinic Examples
Figure 10. Pharmacy Examples
Figure 11. Global Drugs for Vulvovaginal Candidiasis Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 12. Global Drugs for Vulvovaginal Candidiasis Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 13. Global Drugs for Vulvovaginal Candidiasis Sales Quantity (2021-2032) & (K Units)
Figure 14. Global Drugs for Vulvovaginal Candidiasis Price (2021-2032) & (USD/Unit)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Manufacturer in 2025
Figure 16. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2025
Figure 17. Producer Shipments of Drugs for Vulvovaginal Candidiasis by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 18. Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2025
Figure 19. Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2025
Figure 20. Global Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Region (2021-2032)
Figure 21. Global Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Region (2021-2032)
Figure 22. North America Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 23. Europe Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 24. Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 25. South America Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 26. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 27. Global Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 28. Global Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Type (2021-2032)
Figure 29. Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2021-2032) & (USD/Unit)
Figure 30. Global Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 31. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2021-2032)
Figure 32. Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2021-2032) & (USD/Unit)
Figure 33. North America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 34. North America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 35. North America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Country (2021-2032)
Figure 36. North America Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Country (2021-2032)
Figure 37. United States Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 38. Canada Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 39. Mexico Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 40. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 41. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 42. Europe Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Country (2021-2032)
Figure 43. Europe Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Country (2021-2032)
Figure 44. Germany Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 45. France Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 46. United Kingdom Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 47. Russia Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 48. Italy Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 49. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 50. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 51. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Region (2021-2032)
Figure 52. Asia-Pacific Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Region (2021-2032)
Figure 53. China Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 54. Japan Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 55. South Korea Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 56. India Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 57. Southeast Asia Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 58. Australia Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 59. South America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 60. South America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 61. South America Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Country (2021-2032)
Figure 62. South America Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Country (2021-2032)
Figure 63. Brazil Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 64. Argentina Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 65. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Type (2021-2032)
Figure 66. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Application (2021-2032)
Figure 67. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Quantity Market Share by Country (2021-2032)
Figure 68. Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Value Market Share by Country (2021-2032)
Figure 69. Turkey Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 70. Egypt Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 71. Saudi Arabia Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 72. South Africa Drugs for Vulvovaginal Candidiasis Consumption Value (2021-2032) & (USD Million)
Figure 73. Drugs for Vulvovaginal Candidiasis Market Drivers
Figure 74. Drugs for Vulvovaginal Candidiasis Market Restraints
Figure 75. Drugs for Vulvovaginal Candidiasis Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Drugs for Vulvovaginal Candidiasis in 2025
Figure 78. Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
Figure 79. Drugs for Vulvovaginal Candidiasis Industrial Chain
Figure 80. Sales Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
